Clinical Trials

3BP’s most advanced development program IPN01087 / 3BP-227  is currently undergoing Phase I/II clinical testing sponsored by our licensee IPSEN Pharma SAS.

IPN01087 / 3BP-227 is a small molecule antagonist targeting the Neurotensin Receptor I currently tested in the clinical study entitled “An International Multicentre, Open-Label First in Human Phase I/II study to evaluate the safety, tolerability, biodistribution and antitumour activity of 177-Lu-3BP-227 for the treatment of subjects with metastatic or locally advanced cancers expressing Neurotensin Receptor 1 (NTSR1).” Identifier: NCT03525392

EudraCT Number: 2017-001263-20